Moberg Pharma AB announced the appointment of Agneta Larhedas Vice President Pharmaceutical Innovation & Development of Moberg Pharma. Dr. Larhedwill be joining the management team at Moberg Pharma in September. Dr. Larhed has a broad experience of development, regulatory and quality within the pharmaceutical industry. She has held leading positions within the pharmaceutical industry and at regulatory authorities, including the Swedish MPA, Orexo and Q-Med. She is also an expert in the European Pharmacopoeia expert group nr 12 Dosage forms and pharmaceutical technical procedures. She replaces Torbjörn Wärnheim, who leaves the company after eight years at Moberg Pharma.